OnCo

Stay in the loop

Leave your email and OnCo will write when something big changes in cancer research. No spam, one click to unsubscribe.

Email updates open shortly. Until then, press Watch on any page to keep it on your list.

trialsTrialRecruiting

Phase I/II Study: Allogeneic NK-cell Therapy With Chemotherapy for Post-Surgery PDA or Cholangiocarcinoma Patients

A phase 1/2 trial of SLOG + Allogeneic NK cell in pancreatic ductal adenocarcinoma and biliary tract cancer, run by Medigen Biotechnology Corporation, now recruiting.